Skip to main content
. 2022 Jul 22;2022:7831165. doi: 10.1155/2022/7831165

Figure 1.

Figure 1

Risk assessment, treatment, and monitoring for PBC patients. early from advanced disease stage based on LSM by TE (LSM <10 kPa or LSM >10 kPa). ∗∗both parameters normal vs. at least 1 parameter abnormal. ∗∗∗absent or mild fibrosis vs. bridging fibrosis or cirrhosis. ∗∗∗∗repeat TE every 2 years in early stage and every year for advanced disease.